tiprankstipranks
Crescent Biopharma (DE:C68)
FRANKFURT:C68
Germany Market
C68
Crescent Biopharma
RESEARCH TOOLSreports

Crescent Biopharma (C68) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

C68 Analyst Ratings

Strong Buy
7Ratings
Strong Buy
6 Buy
1 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Crescent
Biopharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

C68 Stock 12 Month Forecast

Average Price Target

€27.18
▲(73.12% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Crescent Biopharma in the last 3 months. The average price target is €27.18 with a high forecast of €30.69 and a low forecast of €23.67. The average price target represents a 73.12% change from the last price of €15.70.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"€7","13":"€13","19":"€19","25":"€25","31":"€31"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30.68659965,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€30.69</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.17955969,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€27.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.67251973,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€23.67</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,13,19,25,31],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.9,16.114353819230768,17.328707638461537,18.543061457692307,19.757415276923076,20.971769096153846,22.186122915384615,23.400476734615385,24.614830553846154,25.829184373076924,27.043538192307693,28.257892011538463,29.472245830769232,{"y":30.68659965,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.9,15.844581514615385,16.78916302923077,17.733744543846154,18.67832605846154,19.622907573076922,20.56748908769231,21.512070602307695,22.456652116923078,23.40123363153846,24.345815146153846,25.290396660769233,26.23497817538462,{"y":27.17955969,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.9,15.57480921,16.24961842,16.92442763,17.59923684,18.274046050000003,18.948855260000002,19.62366447,20.29847368,20.97328289,21.6480921,22.32290131,22.99771052,{"y":23.67251973,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.174,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.174,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.174,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.174,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.1,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.5,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.9,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.55,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.1,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.7,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.9,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€30.69Average Price Target€27.18Lowest Price Target€23.67
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on DE:C68
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
€26.3
Buy
67.53%
Upside
Reiterated
06/23/26
Stifel Nicolaus Reaffirms Their Buy Rating on Crescent Biopharma (CBIO)
Piper Sandler Analyst forecast on DE:C68
Biren Amin
Piper Sandler
Piper Sandler
€30.69
Buy
95.46%
Upside
Reiterated
06/23/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Sionna Therapeutics, Inc. (NASDAQ: SION) and Crescent Biopharma (NASDAQ: CBIO)
H.C. Wainwright Analyst forecast on DE:C68
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
―
Hold
―
Downgraded
06/01/26
Crescent Biopharma downgraded to Neutral from Buy at H.C. WainwrightCrescent Biopharma downgraded to Neutral from Buy at H.C. Wainwright
Wedbush Analyst forecast on DE:C68
Robert Driscoll
Wedbush
Wedbush
€23.67
Buy
50.78%
Upside
Reiterated
06/01/26
Analysts Are Bullish on These Healthcare Stocks: Crescent Biopharma (CBIO), IQVIA Holdings (IQV)
LifeSci Capital Analyst forecast on DE:C68
Charles Zhu
LifeSci Capital
LifeSci Capital
€19.29→€24.55
Buy
56.36%
Upside
Reiterated
04/30/26
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), GE Healthcare Technologies Inc (NASDAQ: GEHC) and Crescent Biopharma (NASDAQ: CBIO)
TD Cowen Analyst forecast on DE:C68
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
04/29/26
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Crescent Biopharma (NASDAQ: CBIO) and Guardant Health (NASDAQ: GH)
Guggenheim Analyst forecast on DE:C68
Bradley Canino
Guggenheim
Guggenheim
€30.69
Buy
95.46%
Upside
Reiterated
04/29/26
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (NASDAQ: MBX), Cytokinetics (NASDAQ: CYTK) and Crescent Biopharma (NASDAQ: CBIO)
Jefferies Analyst forecast on DE:C68
Akash Tewari
Jefferies
Jefferies
€30.69
Buy
95.46%
Upside
Reiterated
12/05/25
Jefferies Sticks to Its Buy Rating for Crescent Biopharma (CBIO)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on DE:C68
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
€26.3
Buy
67.53%
Upside
Reiterated
06/23/26
Stifel Nicolaus Reaffirms Their Buy Rating on Crescent Biopharma (CBIO)
Piper Sandler Analyst forecast on DE:C68
Biren Amin
Piper Sandler
Piper Sandler
€30.69
Buy
95.46%
Upside
Reiterated
06/23/26
Analysts Offer Insights on Healthcare Companies: AbbVie (NYSE: ABBV), Sionna Therapeutics, Inc. (NASDAQ: SION) and Crescent Biopharma (NASDAQ: CBIO)
H.C. Wainwright Analyst forecast on DE:C68
Mitchell Kapoor
H.C. Wainwright
H.C. Wainwright
―
Hold
―
Downgraded
06/01/26
Crescent Biopharma downgraded to Neutral from Buy at H.C. WainwrightCrescent Biopharma downgraded to Neutral from Buy at H.C. Wainwright
Wedbush Analyst forecast on DE:C68
Robert Driscoll
Wedbush
Wedbush
€23.67
Buy
50.78%
Upside
Reiterated
06/01/26
Analysts Are Bullish on These Healthcare Stocks: Crescent Biopharma (CBIO), IQVIA Holdings (IQV)
LifeSci Capital Analyst forecast on DE:C68
Charles Zhu
LifeSci Capital
LifeSci Capital
€19.29→€24.55
Buy
56.36%
Upside
Reiterated
04/30/26
Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (NYSE: TEVA), GE Healthcare Technologies Inc (NASDAQ: GEHC) and Crescent Biopharma (NASDAQ: CBIO)
TD Cowen Analyst forecast on DE:C68
Phil Nadeau
TD Cowen
TD Cowen
―
Buy
―
Reiterated
04/29/26
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Crescent Biopharma (NASDAQ: CBIO) and Guardant Health (NASDAQ: GH)
Guggenheim Analyst forecast on DE:C68
Bradley Canino
Guggenheim
Guggenheim
€30.69
Buy
95.46%
Upside
Reiterated
04/29/26
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (NASDAQ: MBX), Cytokinetics (NASDAQ: CYTK) and Crescent Biopharma (NASDAQ: CBIO)
Jefferies Analyst forecast on DE:C68
Akash Tewari
Jefferies
Jefferies
€30.69
Buy
95.46%
Upside
Reiterated
12/05/25
Jefferies Sticks to Its Buy Rating for Crescent Biopharma (CBIO)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Crescent Biopharma

3 Months
Biren AminPiper Sandler
Success Rate
6/14 ratings generated profit
43%
Average Return
+5.04%
Copying Biren Amin's trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of +5.04% per trade.
1 Year
Biren AminPiper Sandler
Success Rate
8/14 ratings generated profit
57%
Average Return
+24.04%
Copying Biren Amin's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +24.04% per trade.
2 Years
Biren AminPiper Sandler
Success Rate
9/14 ratings generated profit
64%
Average Return
+42.54%
Copying Biren Amin's trades and holding each position for 2 Years would result in 64.29% of your transactions generating a profit, with an average return of +42.54% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

C68 Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
10
9
5
7
4
Buy
2
7
6
7
2
Hold
0
0
0
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
16
11
15
7
In the current month, C68 has received 6 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. C68 average Analyst price target in the past 3 months is 27.18.
Each month's total comprises the sum of three months' worth of ratings.

C68 Financial Forecast

C68 Earnings Forecast

Next quarter’s earnings estimate for C68 is -€0.67 with a range of -€0.90 to -€0.47. The previous quarter’s EPS was -€0.60. C68 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year C68 has Performed in-line its overall industry.
Next quarter’s earnings estimate for C68 is -€0.67 with a range of -€0.90 to -€0.47. The previous quarter’s EPS was -€0.60. C68 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year C68 has Performed in-line its overall industry.

C68 Sales Forecast

Next quarter’s sales forecast for C68 is €305.48K with a range of €0.00 to €2.14M. The previous quarter’s sales results were €889.07K. C68 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year C68 has Performed in-line its overall industry.
Next quarter’s sales forecast for C68 is €305.48K with a range of €0.00 to €2.14M. The previous quarter’s sales results were €889.07K. C68 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year C68 has Performed in-line its overall industry.

C68 Stock Forecast FAQ

What is DE:C68’s average 12-month price target, according to analysts?
Based on analyst ratings, Crescent Biopharma’s 12-month average price target is 27.18.
    What is DE:C68’s upside potential, based on the analysts’ average price target?
    Crescent Biopharma has 73.12% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Crescent Biopharma a Buy, Sell or Hold?
          Crescent Biopharma has a consensus rating of Strong Buy, which is based on 6 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Crescent Biopharma’s share price target?
            The average share price target for Crescent Biopharma is 27.18. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €30.69 ,and the lowest forecast is €23.67. The average share price target represents 73.12% Increase from the current price of €15.7.
              What do analysts say about Crescent Biopharma?
              Crescent Biopharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of Crescent Biopharma?
                To buy shares of DE:C68, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.